YUYUE MEDICAL(SZ:002223) Huachuang Securities·2025-05-19 06:35Investment Rating - The report maintains a "Recommendation" rating for Yuyue Medical [1][7]. Core Views - The company achieved a revenue of 7.566 billion yuan in 2024, a decrease of 5.09% year-on-year, with a net profit attributable to the parent company of 1.806 billion yuan, down 24.63% [1][3]. - In Q1 2025, the company reported a revenue of 2.436 billion yuan, an increase of 9.17% year-on-year, while the net profit attributable to the parent company was 625 million yuan, down 5.26% [1][3]. - The report highlights rapid growth in Continuous Glucose Monitoring (CGM) products, which saw over 100% growth in 2024, while the overall business remains stable despite high base effects [7]. Financial Summary - For 2024, total revenue is projected at 7.566 billion yuan, with a year-on-year growth rate of -5.1%. The net profit is expected to be 1.806 billion yuan, with a decline of 24.6% [3][8]. - Forecasts for 2025 to 2027 indicate revenues of 8.560 billion yuan, 9.717 billion yuan, and 11.200 billion yuan, respectively, with corresponding growth rates of 13.1%, 13.5%, and 15.3% [3][8]. - The projected net profit for 2025 is 2.024 billion yuan, reflecting a growth of 12.1% year-on-year, with further increases expected in subsequent years [3][8]. Product Performance - The CGM segment is highlighted for its strong performance, with a 40.20% increase in revenue in 2024, driven by market demand for continuous glucose monitoring solutions [7]. - The respiratory treatment solutions faced challenges with a 22.42% decline in revenue due to high base effects from 2023, although home respiratory devices and nebulizers showed growth [7]. - The home health monitoring solutions segment saw a slight revenue decline of 0.41%, but certain products like electronic blood pressure monitors achieved double-digit growth [7]. Market Position and Future Outlook - The company is actively expanding its product matrix and enhancing its market presence both domestically and internationally, particularly in the CGM and respiratory device sectors [7]. - The report projects a target price of 47 yuan based on a DCF model, indicating a potential upside from the current price of 35.75 yuan [3][7].